OBJECTIVE: To differentiate plasma from ovarian cancer and healthy individuals using MALDI-TOF mass spectroscopy. MATERIALS AND METHODS: MALDI-TOF was used to generate profiles of immuno-depleted plasma samples (89 cancers and 199 healthy individuals) that were fractionated using three types of magnetic beads (HIC8, WCX and IMAC-Cu). RESULTS: Differentially expressed mass ranges showing >1.5-2-fold change in expression from HIC8 (30), WCX (12) and IMAC-Cu (6) fractions were identified. Cross validation and recognition capability scores for the models indicated discrimination between the classes. CONCLUSIONS: Spectral profiles can differentiate plasma samples of ovarian cancer patients from healthy individuals.
OBJECTIVE: To differentiate plasma from ovarian cancer and healthy individuals using MALDI-TOF mass spectroscopy. MATERIALS AND METHODS: MALDI-TOF was used to generate profiles of immuno-depleted plasma samples (89 cancers and 199 healthy individuals) that were fractionated using three types of magnetic beads (HIC8, WCX and IMAC-Cu). RESULTS: Differentially expressed mass ranges showing >1.5-2-fold change in expression from HIC8 (30), WCX (12) and IMAC-Cu (6) fractions were identified. Cross validation and recognition capability scores for the models indicated discrimination between the classes. CONCLUSIONS: Spectral profiles can differentiate plasma samples of ovarian cancerpatients from healthy individuals.